MeSH term | MeSH ID | Detail |
---|---|---|
Sacroiliitis | D058566 | 1 associated lipids |
Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Park SJ et al. | Fulminant and Fatal Multiple Organ Failure in a 12-Year-Old Boy With Mycoplasma pneumoniae Infection. | 2012 | Allergy Asthma Immunol Res | pmid:22211173 |
Hong SJ | The Role of Mycoplasma pneumoniae Infection in Asthma. | 2012 | Allergy Asthma Immunol Res | pmid:22379599 |
Kariyawasam HH and Scadding GK | Chronic rhinosinusitis: therapeutic efficacy of anti-inflammatory and antibiotic approaches. | 2011 | Allergy Asthma Immunol Res | pmid:21966602 |
Siddiqui S and Brightling CE | Airways disease: phenotyping heterogeneity using measures of airway inflammation. | 2007 | Allergy Asthma Clin Immunol | pmid:20525145 |
Xepapadaki P et al. | Atypical bacteria and macrolides in asthma. | 2008 | Allergy Asthma Clin Immunol | pmid:20525132 |
Desrosiers M et al. | Canadian clinical practice guidelines for acute and chronic rhinosinusitis. | 2011 | Allergy Asthma Clin Immunol | pmid:21310056 |
Wedi B et al. | Urticaria and infections. | 2009 | Allergy Asthma Clin Immunol | pmid:20066173 |
Brož P et al. | Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. | 2012 | Allergy | pmid:22435670 |
Igea JM and Lázaro M | Hypersensitivity reaction to clarithromycin. | 1998 | Allergy | pmid:9491242 |
Ben-Shoshan M et al. | Anaphylactic reaction to clarithromycin in a child. | 2009 | Allergy | pmid:19222423 |
Can C et al. | Symmetrical drug-related intertriginous and flexural exanthema induced by two different antibiotics. | Allergol Immunopathol (Madr) | pmid:23253684 | |
Gangemi S et al. | Immediate reaction to clarithromycin. | 2001 Jan-Feb | Allergol Immunopathol (Madr) | pmid:11449533 |
Gaig P et al. | Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study. | 2002 Sep-Oct | Allergol Immunopathol (Madr) | pmid:12396958 |
Karakaya G et al. | Determining safe antibiotics for drug hypersensitive patients with the alternative method of double-triple test. | Allergol Immunopathol (Madr) | pmid:19080798 | |
Malheiro D et al. | Nimesulide-induced fixed drug eruption. | 2005 Sep-Oct | Allergol Immunopathol (Madr) | pmid:16287549 |
Seitz CS et al. | Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing. | Allergol Immunopathol (Madr) | pmid:21269750 | |
Moreira A et al. | Is Helicobacter pylori infection associated with chronic idiopathic urticaria? | Allergol Immunopathol (Madr) | pmid:12890412 | |
Drouet M et al. | [Unusual clinical form of amoxicillin allergy]. | 1996 | Allerg Immunol (Paris) | pmid:9011169 |
Wheeldon TU et al. | The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. | 2004 | Aliment. Pharmacol. Ther. | pmid:15191514 |
Lai KC et al. | Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930902 |
Pilotto A et al. | Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930903 |
Kihira K et al. | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930904 |
Kamada T et al. | Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930905 |
Savarino V et al. | OAM for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930908 |
Perri F et al. | Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421877 |
Perri F et al. | Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421878 |
Pilotto A et al. | Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421879 |
Tepes B et al. | Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421880 |
Calvet X et al. | What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421884 |
Gatta L et al. | A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963079 |
Spinzi G et al. | Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9146769 |
Peterson WL | The role of antisecretory drugs in the treatment of Helicobacter pylori infection. | 1997 | Aliment. Pharmacol. Ther. | pmid:9146787 |
Sierra F et al. | Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. | 2013 | Aliment. Pharmacol. Ther. | pmid:23656465 |
Masaoka T et al. | Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298608 |
Kondo Y et al. | Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298609 |
Chiba N et al. | Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. | 2004 | Aliment. Pharmacol. Ther. | pmid:14984382 |
Di Mario F et al. | Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16611285 |
Madisch A et al. | Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441467 |
Borody TJ et al. | Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441468 |
Veldhuyzen Van Zanten S et al. | One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12786632 |
Molina-Infante J et al. | Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. | 2015 | Aliment. Pharmacol. Ther. | pmid:25776067 |
Wong BC et al. | One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207516 |
Fakheri H et al. | Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207517 |
Nagahara A et al. | Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207518 |
Bardhan KD et al. | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632646 |
Cammarota G et al. | Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632648 |
Gasbarrini A et al. | Efficacy of a multistep strategy for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632649 |
Chan FK et al. | Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632651 |
Pipkin GA et al. | Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768524 |
Fischbach LA et al. | Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. | 2004 | Aliment. Pharmacol. Ther. | pmid:15569109 |
Louw JA et al. | Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768531 |
Laine L et al. | Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768532 |
Vakil N et al. | Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. | 2008 | Aliment. Pharmacol. Ther. | pmid:18774949 |
Shokri-Shirvani J et al. | Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. | 2016 | Aliment. Pharmacol. Ther. | pmid:27137738 |
Axon AT et al. | Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042977 |
Labenz J et al. | One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042978 |
Labenz J et al. | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042979 |
Peitz U et al. | High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860415 |
Sheu BS et al. | Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:12197847 |
Calvet X et al. | One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12144575 |
Di Caro S et al. | Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876707 |
Wu JC et al. | Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876709 |
Mason J et al. | The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876711 |
Calvet X et al. | A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10792124 |
Savarino V et al. | Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:9892878 |
John Albert M et al. | High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. | 2006 | Aliment. Pharmacol. Ther. | pmid:17059517 |
Spinzi GC et al. | Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663722 |
Bazzoli F et al. | Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663723 |
Pozzato P et al. | Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663724 |
Goh KL et al. | Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? | 1997 | Aliment. Pharmacol. Ther. | pmid:9663838 |
Goddard AF et al. | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233187 |
Kolkman JJ et al. | Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663840 |
Miyaji H et al. | Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663841 |
Wong BC et al. | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. | 2000 | Aliment. Pharmacol. Ther. | pmid:11069326 |
Lionetti E et al. | Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:17032283 |
Laurent J et al. | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 2001 | Aliment. Pharmacol. Ther. | pmid:11683693 |
O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
Scott BB | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9570263 |
Goodgame RW et al. | Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736715 |
Malfertheiner P et al. | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. | 2003 | Aliment. Pharmacol. Ther. | pmid:12752349 |
Gené E et al. | Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12752350 |
Sheu BS et al. | The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755841 |
Toracchio S et al. | Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121913 |
You JH et al. | Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421876 |
Cammarota G et al. | Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971300 |
Pilotto A et al. | Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971305 |
Gudjonsson H et al. | High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9845401 |
Vcev A et al. | Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632647 |
Tam YH et al. | Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803605 |
Sengupta S et al. | Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803607 |
Osato MS et al. | Comparative efficacy of new investigational agents against Helicobacter pylori. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284777 |
Nista EC et al. | Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969089 |
Jung YS et al. | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. | 2017 | Aliment. Pharmacol. Ther. | pmid:28497487 |
Klok RM et al. | Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966514 |
Tsuzuki T et al. | Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966545 |
Isomoto H et al. | High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848631 |
Ellenrieder V et al. | Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9701524 |
Miwa H et al. | Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? | 2003 | Aliment. Pharmacol. Ther. | pmid:12823158 |
Lim AG et al. | Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. | 1997 | Aliment. Pharmacol. Ther. | pmid:9218079 |
McNulty CA et al. | Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? | 2012 | Aliment. Pharmacol. Ther. | pmid:22469191 |